ReviewFrontiers in neurology2026
18F-FDG PET/CT for post-cardiac-arrest brain injury: current evidence and future directions.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-cardiac-arrest brain injury is a major cause of death and long-term neurological disability after cardiac arrest, yet current prognostic tools provide limited information on regional cerebral metabolism and functional recovery. Fluorine-18 fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography (18F-FDG PET and PET/CT) provide a molecular imaging approach for evaluating cerebral glucose metabolism after global ischemia-reperfusion injury. This narrative review summarizes the limited preclinical and clinical evidence on the use of 18F-FDG PET and PET/CT in post-cardiac-arrest brain injury, including animal models, small clinical cohorts, studies of disorders of consciousness, and investigations of neuroprotective interventions such as targeted temperature management. Published studies have documented global and regional abnormalities in cerebral glucose uptake; however, the use of these findings to assess injury severity, monitor treatment response, or predict prognosis remains hypothesis-generating. The evidence base is further limited by small sample sizes, heterogeneous imaging protocols, uncertain optimal timing, cost, radiation exposure, and limited feasibility in critically ill patients. Further prospective studies with standardized acquisition, quantification, and interpretation protocols are needed to determine whether 18F-FDG PET or PET/CT can be integrated into multimodal neuroprognostication and therapeutic monitoring after cardiac arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.